{'fraction_non_alphanumeric': 0.023391812865497075, 'fraction_numerical': 0.018193632228719947, 'mean_word_length': 5.416666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Moclobemide and sertraline in the treatment of melancholic and nonmelancholic major depression: a comparative study

The objectives of this study were first to compare the responses to moclobemide and sertraline in melancholic and nonmelancholic major depressive patients and secondly to compare the responses of melancholic and nonmelancholic patients in general. Sixty‐three patients, with diagnosis of major depression according to the DSM‐III‐R criteria were included in the study. In this single blind, comparative, randomized study, 29 patients were treated with moclobemide and 34 patients were treated with sertraline for 13 weeks. A 50 per cent decrease of the HDRS (Hamilton Depression Rating Scale) is defined as response.In intent‐to‐treat analysis the response rates were 69 per cent in the melancholic patients and 59·3 per cent in the nonmelancholic group. The difference is statistically insignificant. According to the intent‐to‐treat analysis in the nonmelancholic group the response rate of the moclobemide‐treated patients was 73·3 per cent, and 41·7 per cent in the sertraline‐treated patients. In the melancholic group the response rate was 82·4 per cent in the sertraline group and 50 per cent in the moclobemide group. Moclobemide was more effective in the nonmelancholic group whilst sertraline was more effective in melancholic group; but the differences were not statistically significant. Due to the small size our findings are tentative and need confirmation using more patients. © 1998 John Wiley & Sons, Ltd.